ADC Therapeutics SA
ADCT · XNYSCIK 1771910fmd_1Z45ZJ43XF8F7TQ3GH6W53TPQRManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2018 to Sep 30, 2026, 29 periods
Latest annual · FY2025
Millions- Total revenues
- 81
- Gross profit
- 76
- Operating income
- (121)
- Net income
- (143)
- Free cash flow
- (141)
Latest quarter · Q3 FY2026
Millions- Total revenues
- 22
- Operating income
- (14)
- Net income
- (25)
- Free cash flow
- (28)
Daily close · ADCTIEX trades only
Nov 09, 2026 to Nov 11, 2026 · 3 sessions1.60 USD
Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- -27.1%
- Revenue, 5 yearsFY2020 to FY2025
- n/m
- Net income, 5 yearsFY2020 to FY2025
- n/m
ADC Therapeutics SA (ADCT) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $81.4 million | $70.8 million | +14.9% | 10-K 2026-03-10 · proof |
| Gross profit | $75.6 million | $64.9 million | +16.4% | 10-K 2026-03-10 · proof |
| Operating income | -$121.5 million | -$130.7 million | 10-K 2026-03-10 · proof | |
| Net income | -$142.6 million | -$157.8 million | 10-K 2026-03-10 · proof | |
| Cash from operating activities | -$141.2 million | -$123.8 million | 10-K 2026-03-10 · proof | |
| Free cash flow | -$141.4 million | -$124.7 million | 10-K 2026-03-10 · proof | |
| Total assets | $323.2 million | $322 million | +0.4% | 10-K 2026-03-10 · proof |
| Total liabilities | $509 million | $524.6 million | -3% | 10-K 2026-03-10 · proof |
| Cash and cash equivalents | $261.3 million | $250.9 million | +4.2% | 10-K 2026-03-10 · proof |
- What was ADC Therapeutics SA (ADCT)'s revenue in fiscal 2025?
- ADC Therapeutics SA (ADCT) reported revenue of $81.4 million for fiscal 2025 (the year ended Dec 31, 2025), against $70.8 million the year before (+14.9%). Source: the 10-K filed with the SEC on Mar 10, 2026. SEC
- What was ADC Therapeutics SA (ADCT)'s gross profit in fiscal 2025?
- ADC Therapeutics SA (ADCT) reported gross profit of $75.6 million for fiscal 2025 (the year ended Dec 31, 2025), against $64.9 million the year before (+16.4%). Source: the 10-K filed with the SEC on Mar 10, 2026. SEC
- What was ADC Therapeutics SA (ADCT)'s operating income in fiscal 2025?
- ADC Therapeutics SA (ADCT) reported operating income of -$121.5 million for fiscal 2025 (the year ended Dec 31, 2025), against -$130.7 million the year before. Source: the 10-K filed with the SEC on Mar 10, 2026. SEC
- What was ADC Therapeutics SA (ADCT)'s net income in fiscal 2025?
- ADC Therapeutics SA (ADCT) reported net income of -$142.6 million for fiscal 2025 (the year ended Dec 31, 2025), against -$157.8 million the year before. Source: the 10-K filed with the SEC on Mar 10, 2026. SEC
- What was ADC Therapeutics SA (ADCT)'s cash from operating activities in fiscal 2025?
- ADC Therapeutics SA (ADCT) reported cash from operating activities of -$141.2 million for fiscal 2025 (the year ended Dec 31, 2025), against -$123.8 million the year before. Source: the 10-K filed with the SEC on Mar 10, 2026. SEC
- What was ADC Therapeutics SA (ADCT)'s free cash flow in fiscal 2025?
- ADC Therapeutics SA (ADCT) reported free cash flow of -$141.4 million for fiscal 2025 (the year ended Dec 31, 2025), against -$124.7 million the year before. Source: the 10-K filed with the SEC on Mar 10, 2026. SEC
- What are ADC Therapeutics SA (ADCT)'s total assets?
- As of Dec 31, 2025, ADC Therapeutics SA (ADCT) reported total assets of $323.2 million, against $322 million a year earlier (+0.4%). Source: the 10-K filed with the SEC on Mar 10, 2026. SEC
- What are ADC Therapeutics SA (ADCT)'s total liabilities?
- As of Dec 31, 2025, ADC Therapeutics SA (ADCT) reported total liabilities of $509 million, against $524.6 million a year earlier (-3%). Source: the 10-K filed with the SEC on Mar 10, 2026. SEC
- What are ADC Therapeutics SA (ADCT)'s cash and cash equivalents?
- As of Dec 31, 2025, ADC Therapeutics SA (ADCT) reported cash and cash equivalents of $261.3 million, against $250.9 million a year earlier (+4.2%). Source: the 10-K filed with the SEC on Mar 10, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:ADCT&period_type=annual&limit=5"Information only, not investment advice.